(HealthDay)—For patients with atrial fibrillation (AF), vitamin K antagonist (VKA) monotherapy is associated with reduced risk of first-time myocardial infarction (MI) and stroke compared with acetylsalicylic acid (ASA) ...
Jun 20, 2017
0
1
(HealthDay)—For young children with presymptomatic Wilson disease, zinc monotherapy is safe and effective, according to a study published online April 28 in the Journal of Gastroenterology and Hepatology.
May 4, 2017
0
0
Dapagliflozin (trade name: Forxiga) has been approved in Germany since November 2012 for the treatment of type 2 diabetes mellitus. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal ...
Jun 6, 2013
0
0
Irish drugmaker Elan Corp. PLC plans to pay $1 billion for the right to future royalties from four respiratory treatments being developed by Theravance Inc. and GlaxoSmithKline.
May 13, 2013
0
0
People with multiple sclerosis (MS) who were treated with combination therapy did not see significant clinical benefit over those treated with single drug therapy, but combination therapy did reduce the development of new ...
Mar 11, 2013
0
0
A recent clinical trial found that interferonβ-1a (INF) and glatiramer acetate (GA), two of the most commonly prescribed drugs for multiple sclerosis (MS), provide no additional clinical benefit when taken together. While ...
Mar 11, 2013
0
0
(HealthDay)—Oral monotherapy with moxifloxacin is as efficacious and safe as combination therapy with ciprofloxacin plus amoxicillin/clavulanic acid for treatment of fever in adult patients with cancer and neutropenia who ...
Jan 30, 2013
0
0
(Medical Xpress)—A new drug for type 2 diabetes, involving research at Aston University is being launched as a once-daily tablet for adults with the condition.
Dec 6, 2012
0
0
Patients with pulmonary arterial hypertension (PAH) receiving combination therapy with intravenous (IV) PGI2 may suffer from greater disease burden compared with those receiving monotherapy or combination therapy, excluding ...
Oct 22, 2012
0
0
Eribulin (trade name: Halaven) was approved in March 2011 for women with locally advanced or metastasizing breast cancer in whom the disease has progressed despite prior drug therapy.
Aug 16, 2012
0
0
